Literature DB >> 21102249

Vascular disrupting agents.

Millie Das1, Heather Wakelee.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 21102249     DOI： 10.1097/01.JTO.0000391376.09556.d8

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  1 in total

1.  A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer.

Authors:  Edward B Garon; Jeffrey D Neidhart; Nashat Y Gabrail; Moacyr R de Oliveira; Jai Balkissoon; Fairooz Kabbinavar
Journal:  Onco Targets Ther       Date:  2016-11-30       Impact factor: 4.147
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.